December 08, 2015
Not intended for U.S. and UK Media - 2015 American Society of Hematology (ASH) Annual Meeting:

New Real World Data of Bayer's Xarelto® in Deep Vein Thrombosis Treatment Confirm Low Rates of Major Bleeding Seen in Pivotal Trial

XALIA is the first published prospective real world study to confirm the benefit of a NOAC in the treatment of patients with deep vein thrombosis (DVT) in routine clinical practice / Real world evidence from CALLISTO Research Programme shows low rates of major bleeding with Xarelto in the treatment of patients with cancer-associated thrombosis / Real world insights expand on pivotal Clinical Trial Programme confirming the safety and effectiveness of Xarelto in a broad range of patients
Berlin, December 8, 2015 - Bayer and its development partner Janssen
Pharmaceuticals, Inc. today announced results from two real world studies - the
non-interventional XALIA study in patients with deep vein thrombosis (DVT) and
a study in patients with cancer-associated thrombosis (CAT) - both showing low
rates of major bleeding and recurrent venous thromboembolism (VTE) with
Xarelto® (rivaroxaban). Results from the two studies were presented at the 2015
ASH Annual Meeting, and XALIA findings were also simultaneously published in
the Lancet Haematology.

"On average, every 37 seconds someone in the Western world dies from a venous
blood clot, so it is important we understand the effectiveness and safety of
available treatment options for these potentially life-threatening blood clots
in real world patient populations," said XALIA Principal Investigator Professor
Alexander G. G. Turpie, McMaster University and Hamilton Health Sciences in
Hamilton, Ontario, Canada. "The real world insights from XALIA confirm the
positive benefit-risk profile of rivaroxaban for the treatment of deep vein
thrombosis that was established in the Phase III EINSTEIN DVT study, endorsing
that these pivotal data for rivaroxaban can be translated to the patients
physicians typically see in everyday clinical practice."

"These important findings from XALIA add to the growing prospective real world
insights, including the previously reported XANTUS and XAMOS studies,
confirming the safety and effectiveness of Xarelto in a broad range of patients
across numerous indications," said Dr Michael Devoy, Member of the Bayer
HealthCare Executive Committee and Chief Medical Officer of Bayer HealthCare.
"At Bayer, we are committed to supporting physicians and the patients they see
every day who are at risk of venous and arterial blood clots."

In the recently initiated CALLISTO Clinical Research Programme Bayer is
exploring the potential benefits of rivaroxaban in patients with cancer. The
risk of VTE is four to seven times higher in patients with active cancer than
in people of the same age without cancer. As part of the CALLISTO programme the
Memorial Sloan Kettering Cancer Center in the U.S. has conducted a Quality
Assurance Initiative (QAI) under which a Clinical Pathway was established to
guide the use of rivaroxaban as an alternative to injectable LMWH for
cancer-associated thrombosis. The study tracked a cohort of 200 patients with
cancer-associated thrombosis and PE or symptomatic proximal DVT, whose full
course of anticoagulation was with rivaroxaban.

In this study rates of major bleeding and recurrent VTE with rivaroxaban were
relatively low based on results from randomized clinical trials with LMWH and
VKA published to date. These results suggest that despite the majority of the
solid tumor patients being at cancer stage IV, the safety and effectiveness of
rivaroxaban is comparable to currently recommended LMWH with the advantage of
reduced patient treatment burden, supporting and validating the ongoing use of
the center's Clinical Pathway Guidelines.

Both XALIA and CALLISTO add to the extensive investigation of rivaroxaban,
which by the time of its completion, is expected to include more than 275,000
patients in both clinical trials and real world settings.


XALIA is the first large-scale, prospective, observational, real world study to
evaluate the safety and effectiveness of a non-VKA oral anticoagulant (NOAC) in
patients with DVT in routine clinical practice. As an oral single-drug therapy,
rivaroxaban demonstrated low rates of major bleeding, recurrent VTE and
all-cause mortality in a broad range of patients. To help address differences
in baseline characteristics between the two treatment groups, a propensity
score analysis was pre-specified in the protocol. In this analysis, major
bleeding was observed in 0.8% of patients in the rivaroxaban group and 2.1% of
patients in the standard anticoagulation group (propensity score-adjusted HR
0.77; 95% CI 0.40-1.50; p=0.44; n.s.), while recurrent VTE occurred in 1.4% and
2.3% of patients respectively (propensity score-adjusted HR 0.91; 95% CI
0.54-1.54; p=0.72; n.s.). All-cause mortality occurred in 0.4% of patients in
the rivaroxaban group compared with 3.4% of patients in the standard
anticoagulation group (propensity score-adjusted HR 0.51; 95% CI 0.24-1.07;
p=0.07; n.s.). Furthermore, XALIA confirmed shorter hospital stays with
rivaroxaban compared to standard anticoagulation therapy, suggesting an
economic benefit by providing simplified treatment management from hospital to
home without the need for injections or routine coagulation monitoring.

XALIA observed the safety and effectiveness of rivaroxaban compared to standard
therapy (usually consisting of initial treatment with unfractionated heparin,
LMWH, or fondaparinux, overlapping with and followed by a VKA) in patients with
objectively confirmed DVT. Type, dose and duration of therapy were at the
discretion of the treating physician.

The prospective, non-interventional study, designed by Bayer HealthCare and in
agreement with the European Medicines Agency (EMA), included 5,142 patients
with DVT from 19 countries in Europe, as well as Canada and Israel, and each
patient was followed up for at least 12 months. Propensity score-adjusted
analyses were performed for 2,505 patients treated with rivaroxaban and 2,010
patients treated with standard anticoagulation therapy, to account for
potential imbalances between the two groups. All reported outcome events were
adjudicated by a blinded Central Committee.


A multi-trial prospective clinical research programme, CALLISTO consists of a
collection of nine clinical studies and Registries. The programme will involve
more than 4,000 patients worldwide to generate new evidence that will help
physicians better manage cancer-associated thrombosis (CAT).

One 200-patient CAT real world evidence study conducted by the Memorial Sloan
Kettering Cancer Center in the U.S. evaluated the use of rivaroxaban as an
alternative to LMWH for treatment of pulmonary embolism (PE) or symptomatic
proximal DVT in patients with advanced cancer. Under a Quality Assurance
Initiative (QAI), which was first started in January 2014, a Clinical Pathway
was established to guide the use of rivaroxaban for CAT.

About Xarelto® (Rivaroxaban)

Rivaroxaban is the most broadly indicated non-vitamin K antagonist oral
anticoagulant (NOAC) and is marketed under the brand name Xarelto®. Xarelto is
approved for seven indications, protecting patients across more venous and
arterial thromboembolic (VAT) conditions than any other NOAC:

- The prevention of stroke and systemic embolism in adult patients with
non-valvular atrial fibrillation (AF) with one or more risk factors

- The treatment of deep vein thrombosis (DVT) in adults

- The treatment of pulmonary embolism (PE) in adults

- The prevention of recurrent DVT and PE in adults

- The prevention of venous thromboembolism (VTE) in adult patients undergoing
elective hip replacement surgery

- The prevention of VTE in adult patients undergoing elective knee replacement

- The prevention of atherothrombotic events (cardiovascular death, myocardial
infarction or stroke) after an Acute Coronary Syndrome in adult patients with
elevated cardiac biomarkers and no prior stroke or transient ischaemic attack
(TIA) when co-administered with acetylsalicylic acid (ASA) alone or with ASA
plus clopidogrel or ticlopidine

Whilst licences may differ from country to country, across all indications
Xarelto is approved in more than 130 countries.

Rivaroxaban was discovered by Bayer HealthCare, and is being jointly developed
with Janssen Research & Development, LLC. Xarelto is marketed outside the U.S.
by Bayer HealthCare and in the U.S. by Janssen Pharmaceuticals, Inc. (Janssen
Research & Development, LLC and Janssen Pharmaceuticals, Inc. are part of the
Janssen Pharmaceutical Companies of Johnson & Johnson.).

Anticoagulant medicines are potent therapies used to prevent or treat serious
illnesses and potentially life-threatening conditions. Before initiating
therapy with anticoagulant medicines, physicians should carefully assess the
benefit and risk for the individual patient.

Responsible use of Xarelto is a very high priority for Bayer, and the company
has developed a Prescribers Guide for physicians and a Xarelto Patient Card for
patients to support best practice.

To learn more, please visit
To learn more about thrombosis, please visit
To learn more about Xarelto, please visit

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of
health care and agriculture. Bayer HealthCare, a subgroup of Bayer AG with
annual sales of around EUR 20.0 billion (2014), is one of the world's leading,
innovative companies in the healthcare and medical products industry and is
based in Leverkusen, Germany. The company combines the global activities of the
Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer
HealthCare's aim is to discover, develop, manufacture and market products that
will improve human and animal health worldwide. Bayer HealthCare has a global
workforce of 60,700 employees (Dec 31, 2014) and is represented in more than
100 countries. More information is available at

Our online press service is just a click away:

Find more information at

Forward-looking statements

This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management. Various
known and unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. These factors
include those discussed in Bayer's public reports which are available on the
Bayer website at The company assumes no liability whatsoever to
update these forward-looking statements or to conform them to future events or